FDA Approves Datapotamab Deruxtecan for HR+/HER2- Metastatic Breast Cancer скачать в хорошем качестве

FDA Approves Datapotamab Deruxtecan for HR+/HER2- Metastatic Breast Cancer

New drug approved for hormone receptor positive/HER2 -negative metastatic breast cancer: datapotamab deruxtecan (Datroway). This medication is in the class of medications of antibody drug conjugates (like Enhertu and Trodelvy). The approval is based on the Tropion-Breast 01 trial, which showed that datapotamab deruxtecan reduced the risk of disease progression or death by 37% when compared to chemotherapy. The progression free survival (time without disease progression or death) was 4.9 months in patients receiving chemotherapy and 6.9 months in patients receiving datapotamab deruxtecan. Patients must have received prior chemotherapy and endocrine therapy for metastatic breast cancer to be eligible to receive this medication. In terms of side effects- we need to monitor for stomatitis (inflammation of mouth/gums), pneumonitis (inflammation of the lungs) and ocular (eye) side effects. More common side effects include nausea, fatigue, elevated liver enzymes, low blood counts and hair loss/thinning. Let me know your questions! #breastcancer #metastaticbreastcancer #mbc